49
Participants
Start Date
September 25, 2019
Primary Completion Date
November 30, 2020
Study Completion Date
November 15, 2022
IPI-549 (eganelisib)
IPI-549 (40mg QD) administered orally in 28-day cycles
Nivolumab
Nivolumab (480mg Q4W) administered intravenously (IV) in 28-day cycles
Placebos
Placebo administered orally in 28-day cycles
Hospital de Sant Creu i Sant Pau, Barcelona
Istituto per la Ricerca e la Cura del Cancro (IRCC), Candiolo
Montefiore Medical Center, The Bronx
Institut Paoli-Calmettes, Marseille
University of MD - Greenebaum Comprehensive Cancer Center, Baltimore
MD Anderson Cancer Center Madrid, Madrid
Hospital Ramón y Cajal, Madrid
Hospital Universitatio HM Sanchinarro, Madrid
Bon Secours St. Francis Cancer Center, Greenville
Institut Claudius Regaud, Toulouse
Hospital Universitario Central de Asturias, Oviedo
Sarah Cannon Tennessee Oncology, Nashville
Hospital Universitario, Seville
Parkview Physicians, Fort Wayne
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola
IMQ Zorrotzaurre, Bilbao
Karmanos Cancer Center, Detroit
Coborn Cancer Center, Saint Cloud
Centre Oscar Lambret, Lille
CHU de Strasbourg, Strasbourg
Istituto Nazionale dei Tumori, Napoli
Onkologicka Klinika, Prague
Centre Antoine Lacassagne, Nice
Oddzial Chorob Rozrostowych Wojewodzki Szpital, Lodz
Dzienny Oddzial Chemioterapii, Racibórz
EXAMEN sp, Skorzewo
Clinical Centre of Serbia, Belgrade
Institute for Oncology of Vojvodina, Kamenitz
ICO Institute Catalan of Oncology, Barcelona
Lead Sponsor
Collaborators (1)
Bristol-Myers Squibb
INDUSTRY
Infinity Pharmaceuticals, Inc.
INDUSTRY